MEDIA

AMS BioteQ was invited to exhibit at the inaugural Japan Pharmaceutical Exhibition.

In pursuit of academic exchange, fostering industry-academia collaboration, and talent cultivation, the School of Pharmacy at Kaohsiung Medical University and AMS BioteQ recently signed a memorandum of understanding (MOU) to enhance industry-academia exchange, promote the development of the domestic biopharmaceutical industry, and lay the foundation for pharmaceutical research talent cultivation.

The "Connecting with Ukraine" economic revitalization event, orchestrated by the Japan International Cooperation Agency (JICA), convened from February 15th to 17th, 2024. This gathering served as a platform uniting businesses, manufacturers, and research institutions from Japan and Ukraine, pooling their resources to aid in the post-war reconstruction endeavors of Ukraine.

On January 18th, AMS BioteQ (TPE: 6864) announced the successful approval of its application for a novel invention patent in Taiwan titled “ARTIFICIAL DRESSING AND USE OF ARTIFICIAL DRESSING FOR PROMOTING WOUND” by the Intellectual Property Office of the Ministry of Economic Affairs, R.O.C.

AMS BioteQ (TPE: 6864) announced on 11th Dec. last year that its innovative medical care product, "SIPSIP Foam," the wound dressing made of its patented bioengineering technology ExtrO, has successfully obtained the registration number issued by the U.S. FDA.

AMS BioteQ (stock code: 6864), a leading biotechnology company, announced on the 21st that its innovative medical care material, "SIPSIP Foam Yuanzhang Cotton Wound Dressing," has successfully obtained approval from the Taiwan Food and Drug Administration (TFDA), with a medical device approval permit number.

In southern Taiwan, there is a significant outbreak of Dengue fever, with the number of infections surpassing thousands of cases this year, reaching a new high for the same period in the past ten years according to statistics from the Centers for Disease Control (CDC). In order to overcome the challenges in treating De

GeneOnline had an exclusive interview with Taiwan’s 元樟生技 AMS BioteQ at the #2023_Medical_Japan_Tokyo.

Medical Japan Tokyo was held grandly from October 11 to 13, gathering medical professionals, manufacturers, medical institutions and research units from around the world. AMS BioteQ Co., Ltd. made its first appearance in the exhibition and became one of the spotlight.

AMS BioteQ: Pioneering Innovation in Antibiotics and Advanced Dressings
Since its establishment in 2018, AMS BioteQ, headquartered in Taiwan, has dedicated itself to the development of cutting-edge antibiotics and antimicrobial dressings.

Despite the ongoing prevalence of dengue fever in Taiwan, the primary method of epidemic prevention in our country still relies on traditional mosquito spray.

AMS BioteQ collaborates with Professor Sheng-Fan Wang, Director of the Center for Tropical Medicine and Infectious Diseases Research at Kaohsiung Medical University